Plasma vs. serum: which is better for proteomic blood biomarker analysis? Evaluation of the novel NULISA platform
Zeng, X.; Farinas, M.; Chen, Y.; Nafash, M. N.; Cohen, A. D.; Lopez, O.; Reis, S. E.; Karikari, T. K.
Show abstract
STRUCTURED ABSTRACTO_ST_ABSINTRODUCTIONC_ST_ABSThe NULISASeq CNS Disease Panel has high potential for AD diagnosis, but the comparability of serum vs. plasma remains unclear. METHODSWe compared its performance on 43 matched serum-plasma pairs from a memory clinic cohort. RESULTSThe panel reproducibly quantified 124 targets (mean CV=4.9%) with high detectability (mean=95.7%). Serum-plasma correlations were strong ({rho}>0.7) for 79 targets. 48 targets had significant NPQ differences, with 32 higher in plasma. Plasma had more erythrocyte-enriched proteins (HBA1, PGK1, SOD1, PRDX6), while serum had more platelet-derived proteins (CD40LG, BDNF, VEGFA, A{beta}40). For classical AD biomarkers, serum-plasma correlations were stronger for p-tau, GFAP, and NfL ({rho}>0.9) than for A{beta} targets ({rho}=0.594- 0.785). Tau levels were higher in plasma; GFAP and NfL were similar, and A{beta} peptides were mixed. Twelve targets, along with p-tau217/A{beta}42, were linked to AD diagnosis, with plasma generally showing stronger effects. DISCUSSIONOur results support serum use but suggest plasma performs better for AD using this panel.
Matching journals
The top 3 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Plasma biomarkers identify brain ATN abnormalities in a dementia-free population-based cohort 97%
- Plasma biomarker profiles and the correlation with cognitive function across the clinical spectrum of Alzheimer’s disease 96%
- Comparison of plasma soluble and extracellular vesicles-associated biomarkers in Alzheimer’s Disease patients and cognitively normal individuals 96%
Similar papers in this journal
- Identifying Proteomic Prognostic Markers for Alzheimer’s Disease with Survival Machine Learning: the Framingham Heart Study 97%
- A conformational variant of p53 (U-p53 AZ ) as blood-based biomarker for the prediction of the onset of symptomatic Alzheimer’s disease 97%
- Plasma brain-derived p-tau217 outperforms other p-tau species in detecting abnormal brain amyloid in an Asian cohort of older people with cerebrovascular disease burden 94%
Similar papers in this journal
- CSF metabolites associate with CSF tau and improve prediction of Alzheimer's disease status 96%
- Plasma p-tau181/Aβ 1-42 ratio predicts Aβ-PET status and correlates with CSF-p-tau181/Aβ 1-42 and future cognitive decline 96%
- Plasma p217+tau vs NAV4694 amyloid and MK6240 tau PET across the Alzheimer continuum 95%
Similar papers in this journal
- Differences between plasma and CSF p-tau181 and p-tau231 in early Alzheimer’s disease 97%
- CSF sphingomyelins in Alzheimer’s disease, neurodegeneration, and neuroinflammation 96%
- The Association of Alzheimer’s Disease-related Blood-based Biomarkers with Cognitive Screening Test Performance in the Congolese Population in Kinshasa 95%